Select Language
OX40
OX40 Overview
| English Name | Tumor necrosis factor receptor superfamily member 4 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 27 | Target Synonym | ATC35 Antigen，OX40 Antigen，ACT35，IMD16，OX40，Receptors， OX40，ACT35 antigen，TNFRSF4，CD134，TNF Receptor Superfamily Member 4，TAX Transcriptionally-Activated Glycoprotein 1 Receptor，CD134 Antigen，TXGP1L，Tumor Necrosis Factor Receptor Superfamily， Member 4，Lymphoid Activation Antigene ACT35，OX40 Homologue，Tumor necrosis factor receptor superfamily member 4，Tax-Transcriptionally Activated Glycoprotein 1 Receptor，OX40 Cell Surface Antigen，OX40L receptor |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | Tumor necrosis factor receptor superfamily member 4 |
| Target Synonym | ATC35 Antigen，OX40 Antigen，ACT35，IMD16，OX40，Receptors， OX40，ACT35 antigen，TNFRSF4，CD134，TNF Receptor Superfamily Member 4，TAX Transcriptionally-Activated Glycoprotein 1 Receptor，CD134 Antigen，TXGP1L，Tumor Necrosis Factor Receptor Superfamily， Member 4，Lymphoid Activation Antigene ACT35，OX40 Homologue，Tumor necrosis factor receptor superfamily member 4，Tax-Transcriptionally Activated Glycoprotein 1 Receptor，OX40 Cell Surface Antigen，OX40L receptor |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 27 |
| Highest Development Stage | Phase 3 Clinical |
OX40 Product List
- Product Category
Protein (15)Cell (2)Kits (2)
- Product Status
Launched (19)
- Species
Human (9)Mouse (3)Cynomolgus / Rhesus macaque (3)Rat (2)Rabbit (1)Canine (1)
- Tag
Fc Tag (5)His Tag (5)Fc Tag & Avi Tag (1)His Tag & Avi Tag (3)Mouse IgG Fc Tag (1)- (4)
- Conjugate
Unconjugated (11)Biotin-labeled (4)- (4)
Total: 19
- 1
- 2
OX40 Background
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.
OX40 Synonyms
TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| OX40 mAb - 01 | Lead | Monoclonal | Humanized Mouse | AutoImmunity | Autoimmune disease |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Rocatinlimab | KHK-4083; AMG-451 | Phase 3 Clinical | Amgen Inc, Kyowa Hakko Kirin Co Ltd | Abdominal Pain; Asthma; Autoimmune Diseases; Colitis; Colitis, Ulcerative; Colonic Diseases; Dermatitis, Atopic; Digestive System Diseases; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Intestinal Diseases; Prurigo Nodularis | Details |
| Ivuxolimab | PF-8600; PF-04518600 | Phase 3 Clinical | Pfizer Inc | Bone metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Triple Negative Breast Neoplasms | Details |
| INBRX-106 | INBRX-106; ES-102; ES102 | Phase 3 Clinical | Inhibrx | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Head and Neck Neoplasms; Melanoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| GSK3174998 | GSK3174998; GSK 3174998; GSK-3174998 | Phase 2 Clinical | Glaxosmithkline Plc | Multiple Myeloma; Neoplasms | Details |
| Telazorlimab | GBR-830; ISB-830 | Phase 2 Clinical | Glenmark Pharmaceuticals Ltd | Dermatitis, Atopic | Details |
| Tavolimab | MEDI-0562 | Phase 2 Clinical | Medimmune | Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms, Squamous Cell; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| HX-111 | HX-111; HX111 | Phase 2 Clinical | Hanx Biopharmaceuticals (Wuhan) Co Ltd | Hematologic Neoplasms; Lymphoma; Solid tumours | Details |
| CS-01 | CS01; CS-01 | Phase 2 Clinical | Zhongshan Constimulus Bio Co Ltd | Solid tumours | Details |
| Brivekimig | SAR-442970; SAR442970 | Phase 2 Clinical | Sanofi | Colitis, Ulcerative; Crohn Disease; Diabetes Mellitus, Type 1; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Hidradenitis Suppurativa; Inflammation; Nephrosis | Details |
| IMG-007 | IMG-007 | Phase 2 Clinical | Alopecia Areata; Dermatitis, Atopic; Eczema | Details | |
| BAT-6026 | BAT-6026 | Phase 2 Clinical | Bio-Thera Solutions Ltd, Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Autoimmune Diseases; Dermatitis, Atopic; Solid tumours | Details |
| Gimistotug | BGB-A445 | Phase 2 Clinical | BeOne Medicines Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Melanoma; Nasopharyngeal Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Recombinant human anti-OX40 monoclonal antibody (Livzon Group) | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Neoplasms | Details | |
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Shattuck Labs Inc, Takeda Pharmaceutical Co Ltd | Adenocarcinoma; Astrocytoma; Carcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| FS-120 | FS-120 | Phase 1 Clinical | F-Star | Neoplasm Metastasis; Neoplasms | Details |
| Cudarolimab | IBI-101 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| Revdofilimab | ABBV-368; PR-1628103 | Phase 1 Clinical | Abbvie Inc | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| SHR-1806 | SHR-1806 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | Neoplasms | Details |
| BMS-986178 | BMS-986178 | Phase 1 Clinical | Bristol-Myers Squibb Company | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Neoplasms; Solid tumours; Waldenstrom Macroglobulinemia | Details |
| EMB-09 | EMB-09 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hepatitis B, Chronic; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| PeptiCRAd-1 | Valo-D102; PeptiCRAd-1 | Phase 1 Clinical | Valor Biotherapeutics | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liposarcoma, Myxoid; Neoplasms; Osteosarcoma; Sarcoma; Sarcoma, Synovial; Skin Melanoma; Triple Negative Breast Neoplasms | Details |
| Cenzestotug | YH-002 | Phase 1 Clinical | Solid tumours | Details | |
| SAR-446422 | SAR446422; SAR-446422 | Phase 1 Clinical | Sanofi | Autoimmune Diseases | Details |
| STAR-0310 | ISB-830-X8; STAR-0310; STR-310 | Phase 1 Clinical | Ichnos Sciences Inc | Dermatitis, Atopic | Details |
| HFB-3010 | HFB-301001; HFB-3010 | Phase 1 Clinical | HiFiBiO Therapeutics | Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Melanoma; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Neoplasms | Details |
| HLX-51 | HLX-51 | Phase 1 Clinical | Lymphoma; Solid tumours | Details | |
| MEDI-6469 | MEDI-6469; AGX-051 | Phase 1 Clinical | AgonOx Inc, Astrazeneca Plc, Providence Cancer Center, Providence Health & Services | Colorectal Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Neoplasms; Prostatic Neoplasms; Solid tumours | Details |
- Overview
- Product List
- Clinical Drug Information
Share to: